COMBINATION THERAPY FOR THE TREATMENT OF SOLID AND HEMATOLOGICAL CANCERS

摘要

Methods are provided for using anti-CD47 mAbs as therapeutics for the prevention and treatment of solid and hematological cancers, with other anti-cancer agents, which include but are not limited to proteasome inhibitors, immunomodulatory agents, Bruton's tyrosine kinase (BTK) inhibitors, BCMA-targeting agents, CAR-T cells, anthracyclines, platinums, taxols, cyclophosphamides, topisomerase inhibitors, anti-metabolites, anti-tumor antibiotics, mitotic inhibitors, alkylating agents, and demethylating agents.